Biogen Inc. investors will have another chance to prove some of their claims that the pharmaceutical company violated federal securities laws in the way it presented data about the efficacy of its expensive Alzheimer’s drug, Aduhelm.
Allie Reed is a Health Care Reporter at various esteemed publications. She focuses on the intersection of health care and cryptocurrency, exploring topics such as crypto exchanges, crypto regulation, and the broader implications of cryptocurrency in the health sector. Allie's work has been featured in Our Community Now, Bloomberg Law, Los Angeles Times, BNN Bloomberg, Bloomberg News, Lincoln Times News, and the Analytics on Fire Podcast.